Description
Research Overview
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that has been investigated extensively in research involving growth hormone secretion, IGF-1 signalling, metabolic physiology and body-composition regulation.
Research Focus
Research has examined tesamorelin in relation to stimulation of endogenous growth hormone release, subsequent changes in IGF-1, visceral adipose tissue and metabolic markers. Clinical studies have investigated its effects in specific populations, including people with HIV-associated abdominal fat accumulation and individuals with obesity and reduced growth hormone secretion.
Scientific Context
Tesamorelin acts through the GHRH receptor pathway to stimulate endogenous growth hormone secretion. Human clinical research has demonstrated changes in growth hormone and IGF-1 signalling, while controlled studies have also investigated changes in visceral adipose tissue and other metabolic parameters. The findings are specific to the populations, formulations and protocols studied and should not be generalized to unrelated applications.
Important Research Note
Tesamorelin has been studied extensively in human clinical research and has an established regulatory indication in a specific medical context in the United States. However, this AXEN LABS product is supplied strictly for research purposes. Research findings should not be interpreted as evidence that this product is suitable for weight management, body composition, performance enhancement, treatment of disease or any other human application.
For research purposes only. Not intended for human or veterinary use.
